Chronic hepatitis B: Update of recommendations
Chronic hepatitis B: Update of recommendations
复制标题
DOI：
10.1002/hep.20110
复制
发表时间：
2004-03-01
期刊：
影响因子：
13.5
通讯作者：
McMahon, BJ
中科院分区：
文献类型：
--
作者：
Lok, ASF;McMahon, BJ
据估计，全世界有3.5亿人感染乙型肝炎病毒（HBV），美国有125万人感染乙肝病毒。乙型肝炎携带者有发展为肝硬化和肝细胞癌（HCC）的风险。慢性乙型肝炎病毒感染的自然史是可变的。慢性HBV感染者需要终身监测，以确定是否以及何时需要抗病毒治疗干预，并观察是否有严重的后遗症。这些指南是在美国肝病研究协会实践指南委员会的主持下制定并经其批准的。最初的指南发表在《国际肝病》2001年；34: 1225 - 1241。鉴于最近的进展，特别是在慢性乙型肝炎的治疗方面，这些指南于2003年9月进行了更新。最新指南的完整版本，包括对最近发表的文献的回顾，可以在AASLD网站上找到。带给我们。org。以下是最新的慢性乙型肝炎治疗建议的总结。这些建议分为I（随机对照试验）、II-1（非随机对照试验）、II-2（队列或病例对照分析研究）、II-3（多时间序列、戏剧性的非对照实验）和III（权威人士的意见、描述性流行病学）。
An estimated 350 million persons worldwide and 1.25 million in the United States are infected with hepatitis B virus (HBV). Hepatitis B carriers are at risk for development of cirrhosis and hepatocellular carcinoma (HCC). The natural history of chronic HBV infection is variable. Persons with chronic HBV infection need lifelong monitoring to determine if and when intervention with antiviral therapy is needed and to observe for serious sequelae. These guidelines were developed under the auspices of, and approved by, the Practice Guidelines Committee of the American Association for the Study of Liver Diseases. The original guidelines were published in HEPATOLOGY 2001; 34: 1225–1241. 1 In light of recent progress, particularly in the treatment of chronic hepatitis B, these guidelines were updated in September of 2003. A complete version of the updated guidelines, including a review of recently published literature, can be found at the AASLD web site, www. aasld. org. Following is a summary of the updated recommendations for treatment of chronic hepatitis B. The recommendations were graded as I (randomized controlled trials), II-1 (controlled trials without randomization), II-2 (cohort or case-control analytic studies), II-3 (multiple time series, dramatic uncontrolled experiments), and III (opinions of respected authorities, descriptive epidemiology).